Dosage Forms & Drug Delivery Systems – Page 24

Emulsion Inversion after packaging change: cleaning validation and worst-case selection

Identifying symptoms of emulsion inversion is crucial to initiating an effective investigation. Some common observable signs include:Click to read the full article.

E&L Failure after backing material change: GMP investigation plan and CAPA

Devising an Effective GMP Investigation for E&L Failure Following Backing Material Change In the realm of pharmaceutical manufacturing, the integrity and efficacy of transdermal drug delivery systems hinge on meticulous…

Ccit Failure during method transfer: FDA-ready investigation report and batch disposition

CCIT failures can manifest in various ways, indicating potential issues in method transfer or laboratory processes. Key symptoms to monitor include:Click to read the full article.

Edge Lifting after adhesive change: root cause mapping across materials and process

Identifying symptoms and signals is the crucial first step in any investigation. Symptoms of edge lifting after adhesive change can manifest in various ways:Click to read the full article.

Viscosity Drift during bulk hold: GMP investigation and CAPA strategy

The first step in addressing viscosity drift is identifying the symptoms or signals that suggest an issue may be present. Common observations include:Click to read the full article.

Backing Delamination at accelerated stability: process parameter review and validation impact

Identifying the symptoms or signals associated with backing delamination is crucial for initiating timely investigations. Symptoms can manifest at various stages of the manufacturing process, particularly during stability testing:Click to…

Ph Drift during homogenization: mixing and sampling controls for QA review

Understanding the symptoms of pH drift is essential for prompt identification and resolution. Indicators to look for include:Click to read the full article.

E&L Failure during method transfer: sampling, filtration, and EM controls

Identifying initial symptoms of E&L failures is critical in enabling timely intervention. Symptoms may manifest as:Click to read the full article.

Drug Crystallization after backing material change: GMP investigation plan and CAPA

Identifying early symptoms or signals of drug crystallization is critical in averting production delays and product recalls. Common observations include:Click to read the full article.

Texture Variability during shared equipment campaign: GMP investigation and CAPA strategy

Identifying early signals of texture variability is critical in minimizing production impact and ensuring product quality. Symptoms can manifest as:Click to read the full article.

Ivpt Failure in transdermal patch manufacturing: packaging integrity and shelf-life justification

Identifying symptoms or signals indicative of IVPT failures starts with comprehensive monitoring of both the manufacturing process and the final product. Key symptoms that may signal potential issues include:Click to…

Texture Variability at accelerated stability: packaging compatibility and stability justification

Upon conducting accelerated stability testing, the following symptoms may indicate texture variability:Click to read the full article.